Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - V.I. Technologies, Inc. (NasdaqNM:VITX)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials | Reports
Location
134 Coolidge Avenue
Watertown, MA 02472
Phone: (617) 926-1551
Fax: (617) 923-2276
Email: ir@vitechnologies.com
Employees (last reported count): 236
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Products & Services
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 71%
·Institutional: 30% (105% of float)
(38 institutions)
·Net Inst. Buying: 802.0K shares (+10.40%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
V.I. Technologies, Inc. (VITEX) develops biotech products designed to ensure a safer transfusion blood supply. The Company's produces INACTINE Pathogen Inactivation, a technology that inactivates blood-borne pathogens. The INACTINE Pathogen Inactivation red blood cell product, currently in a Phase II clinical trial, is designed to inactivate pathogens contained in red blood cells, the largest transfusion market segment. Universal PLA+SD, currently in Phase III clinical trials, is the initial product from VITEX 's Affinity Purification technology platform. The Company maintains development and commercialization partnerships with Pall Corporation, Amersham Pharmacia Biotech, Haemonetics, Inc., the American National Red Cross and Bayer Corporation. In August 2001, the Company divested its plasma operations. The plasma operations are responsible for producing intermediate plasma fractions and virally inactivated transfusion plasma, PLAS+SD.
More from Market Guide: Expanded Business Description

Financial Summary
VITX is a developer of a broad portfolio of blood products and systems using its proprietary viral inactivation technologies. For the 26 weeks ended 6/30/01, net revenues fell 4% to $20.3 million. Net loss totaled $18.8 million, up from $5.4 million. Revenues reflect lower sales from the PLAS+/R/SD business and the absence of a $600 thousand credit from the Red Cross Incentive Program. Higher losses reflect increased spending on the INACTINE/TM/ red cell pathogen inactivation program.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Samuel Ackerman, M.D., 53
Chairman
$365K
John Barr, 44
Pres, CEO
462K
Thomas Higgins, 49
CFO and Exec. VP of Operations
285K
Bernadette Alford, Ph.D., 51
Exec. VP, Regulatory and Clinical Affairs
117K
Dollar amounts are as of 30-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:VITXAs of 31-Aug-2001
Price and Volume
52-Week Low
on 20-Dec-2000
$3.75 
Recent Price$7.79 
52-Week High
on 29-June-2001
$12.85 
Beta0.82 
Daily Volume (3-month avg)53.4K
Daily Volume (10-day avg)23.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change+13.3%
52-Week Change
relative to S&P500
+52.0%
Share-Related Items
Market Capitalization$176.7M
Shares Outstanding22.7M
Float6.60M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$1.63 
Earnings (ttm)-$1.33 
Earnings (mrq)-$0.64 
Sales (ttm)$1.94 
Cash (mrq)$0.39 
Valuation Ratios
Price/Book (mrq)4.79 
Price/EarningsN/A 
Price/Sales (ttm)4.01 
Income Statements
Sales (ttm)$40.6M
EBITDA (ttm)-$13.6M
Income available to common (ttm)-$28.5M
Profitability
Profit Margin (ttm)-70.1%
Operating Margin (ttm)-45.1%
Fiscal Year
Fiscal Year EndsDec 30
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-44.76%
Return on Equity (ttm)-62.12%
Financial Strength
Current Ratio (mrq)1.62 
Debt/Equity (mrq)0.10 
Total Cash (mrq)$8.77M
Short Interest
As of 8-Aug-2001
Shares Short45.0K
Percent of Float0.7%
Shares Short
(Prior Month)
67.0K
Short Ratio1.55 
Daily Volume29.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.